Topical Liposomal Amphotericin B Gel Treatment for Cutaneous Leishmaniasis

• Status: Recruiting
• Trial end date: 2022-01-01
• Target enrollment: 0
• Participant gender: All

Summary

Comparison between placebo gel treatment to topical liposomal amphotericin B gel treatment for cutaneous leishmaniasis of Leishmania species major and tropica.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Soroka University Medical Center
• Treatments: Amphotericin B; Liposomal amphotericin B

Criteria

Inclusion Criteria:

• Cutenous leishmaniasis confirmed by PCR (Leishmania species major or tropica)

• 1 to 5 lesions

• Signed informed consent

Exclusion Criteria:

• Facial lesions

• Significant co-morbidity

• Pregnancy or breast-feeding at enrollment

• Previous treatment for leishmaniasis